Marco Meglio

The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]

The vice president of scientific engagement at the Alzheimer's Association discussed new data on amyloid-targeting therapies, expanded diagnostic tools, and emerging clinical guidelines for Alzheimer disease presented at AAIC 2025. [WATCH TIME: 5 minutes]

Bio-Thera Solutions announced that its pivotal trial of BAT4406F, an anti-CD20 monoclonal antibody, for neuromyelitis optica spectrum disorder will close enrollment early after achieving statistically significant efficacy.

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

New findings from a randomized trial reported no difference in relapse rates or new T2 lesions between a personalized lifestyle app and a nonpersonalized version for multiple sclerosis.

A recent study reveals GLP-1 receptor agonists significantly reduce medication use and symptoms in idiopathic intracranial hypertension patients, suggesting a promising management strategy.

Eisai and Biogen seek FDA approval for a convenient, at-home Alzheimer’s treatment option, enhancing patient flexibility and reducing costs.

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

Semaglutide significantly reduced the risk of heart attack, stroke, and death compared to tirzepatide in patients with obesity and cardiovascular disease.

Impaired kidney function significantly increases the risk of recurrent ischemic stroke, highlighting the need for tailored treatment strategies in high-risk patients.

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]

Research reveals that increased sedentary time significantly impacts neurodegeneration and cognitive decline in older adults, especially those genetically at risk for Alzheimer’s.

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the link between iRBD and neurodegeneration.

The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about how to ensure a smooth transition from pediatric to adult epilepsy care for university students. [WATCH TIME: 4 minutes]

The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.

Revalesio's RNS60 gains FDA fast track status, offering a groundbreaking approach to neuroprotection in ischemic stroke treatment.

Long-term data confirms givinostat's safety and efficacy in delaying Duchenne muscular dystrophy progression, offering hope for patients and families.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

Amylyx Pharmaceuticals discontinued its AMX0035 program for progressive supranuclear palsy after a phase 2b trial failed to show efficacy.

MediciNova's COMBAT-ALS trial reaches full enrollment, exploring ibudilast's potential to treat ALS and improve patient outcomes.

The neurophysiologist at Allegheny Health Network shared his clinical experience with tofersen in patients with SOD-1 ALS, while emphasizing the critical role of accessible genetic testing for patient identification. [WATCH TIME: 3 minutes]

A pivotal phase 3 study explores ampreloxetine's potential to treat neurogenic orthostatic hypotension in multiple system atrophy patients, aiming for FDA approval.

Merz initiates phase 3 trials for Xeomin, targeting migraine prevention in adults, aiming to fill gaps in current treatment options.

Tracey Dawson, PhD, senior vice president of U.S. Therapeutic Area Head of Neuroscience at Novartis, expanded on the recently launched SMAshing My Limits campaign, a community-driven project aimed to address needs of developing teens with SMA.

The vice chair of education for the department of neurology at Mass General outlined her AUPN 2025 session on supporting clinician educators through recognition, career development, and institutional frameworks for advancement. [WATCH TIME: 4 minutes]

The head of the neurology department at Vall d’Hebron University Hospital provided clinical thoughts on fremanezumab’s expanded approval in pediatric migraine, the phase 3 SPACE study, and where future treatment may hold.

Serum NPTX2 emerges as a novel biomarker in ALS, with combined NPTX2 and NfL levels improving survival prediction and disease monitoring.